Efficacy and safety of the fixed-dose combination regimen of MK3 [MK-3682/grazoprevir/ruzasvir] with or without ribavirin in non-cirrhotic or cirrhotic patients with chronic HCV GT1, 2, 3, 4 or 6 infection (Parts A & B of C-CREST-1 & 2)
2017 ◽
Vol 66
(1)
◽
pp. S315-S316
◽
Keyword(s):
Keyword(s):
2017 ◽
Vol 48
(2)
◽
pp. 198-207
◽
Keyword(s):
Keyword(s):